Next Article in Journal
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Next Article in Special Issue
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Previous Article in Journal
Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers
Previous Article in Special Issue
Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma
Open AccessReview

Immunotherapy for Multiple Myeloma

1
Department of Hematology, Nippon Medical School, Tokyo 113-8603, Japan
2
Department of Microbiology and Immunology, Nippon Medical School, Tokyo 113-8603, Japan
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(12), 2009; https://doi.org/10.3390/cancers11122009
Received: 2 November 2019 / Revised: 10 December 2019 / Accepted: 11 December 2019 / Published: 12 December 2019
(This article belongs to the Special Issue Latest Development in Multiple Myeloma)
Despite therapeutic advances over the past decades, multiple myeloma (MM) remains a largely incurable disease with poor prognosis in high-risk patients, and thus new treatment strategies are needed to achieve treatment breakthroughs. MM represents various forms of impaired immune surveillance characterized by not only disrupted antibody production but also immune dysfunction of T, natural killer cells, and dendritic cells, although immunotherapeutic interventions such as allogeneic stem-cell transplantation and dendritic cell-based tumor vaccines were reported to prolong survival in limited populations of MM patients. Recently, epoch-making immunotherapies, i.e., immunomodulatory drug-intensified monoclonal antibodies, such as daratumumab combined with lenalidomide and chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen, have been developed, and was shown to improve prognosis even in advanced-stage MM patients. Clinical trials using other antibody-based treatments, such as antibody drug-conjugate and bispecific antigen-directed CD3 T-cell engager targeting, are ongoing. The manipulation of anergic T-cells by checkpoint inhibitors, including an anti-T-cell immunoglobulin and ITIM domains (TIGIT) antibody, also has the potential to prolong survival times. Those new treatments or their combination will improve prognosis and possibly point toward a cure for MM. View Full-Text
Keywords: multiple myeloma; immunotherapy; antibody drug-conjugate (ADC); bispecific antigen-directed CD3 T-cell engager; chimeric antigen receptor T-cell (CAR-T) therapy; immune checkpoint inhibitor; tumor vaccine; allogeneic stem cell transplantation multiple myeloma; immunotherapy; antibody drug-conjugate (ADC); bispecific antigen-directed CD3 T-cell engager; chimeric antigen receptor T-cell (CAR-T) therapy; immune checkpoint inhibitor; tumor vaccine; allogeneic stem cell transplantation
Show Figures

Figure 1

MDPI and ACS Style

Tamura, H.; Ishibashi, M.; Sunakawa, M.; Inokuchi, K. Immunotherapy for Multiple Myeloma. Cancers 2019, 11, 2009.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop